Baudax Bio (BXRX) Stock Forecast, Price & News

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Baudax Bio in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" BXRX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BXRX, but not buy additional shares or sell existing shares.
View BXRX analyst ratings or view top-rated stocks.

1 Wall Street analysts have issued 12-month target prices for Baudax Bio's stock. Their BXRX share price forecasts range from $40.00 to $40.00. On average, they anticipate the company's share price to reach $40.00 in the next year. This suggests a possible upside of 7,517.6% from the stock's current price.
View analysts price targets for BXRX or view top-rated stocks among Wall Street analysts.

Baudax Bio's stock was trading at $3.18 at the beginning of 2023. Since then, BXRX shares have decreased by 83.5% and is now trading at $0.5251.
View the best growth stocks for 2023 here.

Baudax Bio saw a decrease in short interest in the month of May. As of May 15th, there was short interest totaling 88,000 shares, a decrease of 90.0% from the April 30th total of 876,300 shares. Based on an average daily volume of 1,170,000 shares, the short-interest ratio is presently 0.1 days. Approximately 3.4% of the shares of the company are sold short.
View Baudax Bio's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023.
View our BXRX earnings forecast.

Baudax Bio, Inc. (NASDAQ:BXRX) released its earnings results on Thursday, November, 4th. The company reported ($4.00) EPS for the quarter, missing the consensus estimate of ($3.20) by $0.80. The firm earned $0.28 million during the quarter, compared to analyst estimates of $0.60 million. Baudax Bio had a negative trailing twelve-month return on equity of 1,050.53% and a negative net margin of 4,629.45%. During the same period last year, the company posted ($14.40) EPS.

Baudax Bio's stock reverse split on the morning of Wednesday, November 30th 2022. The 1-40 reverse split was announced on Wednesday, November 30th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, November 30th 2022. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some companies that other Baudax Bio investors own include Sorrento Therapeutics (SRNE), Coty (COTY), NIO (NIO), VBI Vaccines (VBIV), ADMA Biologics (ADMA), Energy Transfer (ET), Remark (MARK), Designer Brands (DBI), Geron (GERN) and Matinas BioPharma (MTNB).

Baudax Bio trades on the NASDAQ under the ticker symbol "BXRX."

Baudax Bio's stock is owned by a variety of institutional and retail investors. Top institutional investors include Susquehanna International Group LLP (1.27%). Insiders that own company stock include Arnold M Baskies, Geraldine Henwood, Richard S Casten and Winston J Churchill.
View institutional ownership trends.

Shares of BXRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of BXRX stock can currently be purchased for approximately $0.53.

Baudax Bio (NASDAQ:BXRX) has a market capitalization of $3.18 million and generates $1.27 million in revenue each year. The company earns $-58,790,000.00 in net income (profit) each year or ($148.22) on an earnings per share basis.

Baudax Bio's mailing address is 490 LAPP ROAD, MALVERN PA, 19355. The official website for the company is www.baudaxbio.com. The company can be reached via phone at 484-395-2440, via email at sam@argotpartners.com, or via fax at 484-395-2471.